Video

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Steven Kaplan, MD, professor of Urology, Icahn School of Medicine at Mount Sinai, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Results from a study presented during the 2021 AUA Annual Meeting showed that real-world surgical retreatment rates are higher than what has previously been reported in this patient population, according to Kaplan. This is true even for standard procedures, such as transurethral resection of the prostate (TURP).

Results included that compared with TURP, GreenLight, and UroLift, patients who received Rezum steam injection experienced the highest rates of surgical retreatment in 1 year, Kaplan says.

These real-world data are important, as they may possess the potential to inform treatment decisions for these patients, Kaplan concludes. 

Related Videos
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD